Egyptian HCV Patient Treatment Data with Liver Fibrosis Prediction Model

A 2017 dataset of Egyptian patients who underwent Hepatitis C Virus treatment dosages for about 18 months. The data includes demographic, symptom, blood test, and liver enzyme measurements over multiple weeks, intended for a non-invasive liver fibrosis prediction model. It was created by Mahmoud Nasr, Khaled El-Bahnasy, M. Hamdy, and S. Kamal and published in the International Computer Engineering Conference.

Use Cases

• Predicting liver fibrosis based on non-invasive blood test and symptom data mentioned in the description.
• Analyzing treatment response over time based on alanine transaminase (ALT) and RNA measurements at multiple intervals.
• Modeling the relationship between baseline histological grading and patient demographic or clinical features.
• Studying symptom prevalence and progression in Egyptian HCV patients undergoing treatment.

Strengths

• Includes longitudinal measurements for key biomarkers (ALT, RNA) at multiple time points up to 48 weeks.
• Covers a range of data types: demographic, symptomatic, hematological, and histological features.
• Based on expert recommendations for data discretization, suggesting clinical relevance.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

OpenML, with original authors Nasr, M., El-Bahnasy, K., Hamdy, M., & Kamal, S. M.

Collection Method

Collected from Egyptian patients undergoing HCV treatment.

Time Range

Treatment period of about 18 months; publication year 2017.

Freshness

Publication date is 2017; last update date is unknown.

Geography

Egypt